Limiting Limited Liability in Copyright Infringement Suits

Photo: liability by Marco Verch under CC BY 2.0 Mike Chernoff, Associate Member, University of Cincinnati Law Review I. Introduction A copyright holder has the exclusive right to reproduce his copyrighted work, prepare derivative works, and distribute copies of the work.[1] If these rights are violated, the party responsible for the violation can be found to have infringed on the... Continue Reading →

The State of Personalized Medicine in Patent Law

"DNA" by e.coers is licensed under CC BY-SA 2.0. Kris Schroder, University of Cincinnati Law Review I. INTRODUCTION In his 2015 State of the Union Address, President Barack Obama launched the Precision Medicine Initiative, which would โ€œlead a new era of medicine -- one that delivers the right treatment at the right time.โ€[1] The mission... Continue Reading →

Planting Innovation: A Look into Plant Patent Protection and the Deficiencies of the Plant Protection Act and Plant Variety Protection Act

Author: Ashley J. (Clever) Earle, Contributing Member, University of Cincinnati Law Review When thinking about patent protection, most individuals likely picture what patent attorneys describe as a โ€œwidgetโ€โ€”a physical, mechanical invention. Patent protection however, covers a much broader spectrum of inventions. It may seem natural to grant patents to protect new innovations such as chemical... Continue Reading →

The โ€œBlurred Linesโ€ of Copyright Scope

Author: Jon Siderits, Associate Member, University of Cincinnati Law Review On March 10, 2015, a federal jury found that Robin Thicke and Pharrell Williams infringed a copyright owned by the heirs of Marvin Gaye, by copying substantially from Gayeโ€™s song โ€œGot to Give It Upโ€ when they created their 2013 hit โ€œBlurred Lines.โ€[1] While other... Continue Reading →

Federal Circuit No Longer to Review Patent Claim Construction Entirely De Novo

Author: Jon Siderits, Associate Member, University of Cincinnati Law Review On January 20, 2015, the Supreme Court announced its decision in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., and did away with the Federal Circuitโ€™s longstanding application of a purely de novo standard when reviewing a district courtโ€™s construction of a patent claim.[1] Specifically, the... Continue Reading →

Up ↑

Skip to content